2. Search Result
Search Result
Results for "

nicotinamide adenine dinucleotide

" in MedChemExpress (MCE) Product Catalog:

40

Inhibitors & Agonists

1

Fluorescent Dyes

7

Biochemical Assay Reagents

4

Natural
Products

4

Isotope-Labeled Compounds

1

Oligonucleotides

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0445
    NAD+
    40+ Cited Publications

    β-DPN; β-NAD; β-nicotinamide adenine dinucleotide

    		 Endogenous Metabolite Metabolic Disease
    NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
    NAD+
  • HY-B0445A
    NAD sodium
    40+ Cited Publications

    β-DPN sodium; β-NAD sodium; β-nicotinamide adenine dinucleotide sodium

    		 Endogenous Metabolite Metabolic Disease
    NAD sodium is an orally effective cofactor and homeostatic regulator. NAD sodium can be reduced to β-nicotinamide adenine dinucleotide (NADH) during coupling with reactions that oxidize organic substrates. NAD sodium can be converted to β-nicotinamide adenine dinucleotide (NADH) and passes to the inside of mitochondria, which indirectly generates ATP. NAD sodium can be used for the research of non-alcoholic fatty liver disease, obesity, and glucose intolerance .
    NAD sodium
  • HY-113432
    Nudifloramide

    2PY

    		 Endogenous Metabolite PARP Metabolic Disease
    Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .
    Nudifloramide
  • HY-P2804
    GAPDH, rabbit muscle
    1 Publications Verification

    GADPH; G3PDH; Glyceraldehyde phosphate dehydrogenase

    		 Endogenous Metabolite Others
    Glyceraldehyde phosphate dehydrogenase (EC 1.2.1.12) is the target of anti-thymocyte and anti-apoptotic agents. Glyceraldehyde phosphate dehydrogenase catalyzes the chain oxidation of reduced nicotinamide adenine dinucleotide by perhydroxyl radicals .
    GAPDH, rabbit muscle
  • HY-150508
    MK-0159
    1 Publications Verification

    		 CD38 Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    MK-0159 is an orally active, potent and selective CD38 inhibitor, with IC50 values of 22, 3, and 70 nM for human, mouse and rat CD38, respectively. MK-0159 also shows good microsomal stability for human and rodent liver microsomes. MK-0159 increases NAD + (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart .
    MK-0159
  • HY-113472
    N-Methyl-4-pyridone-3-carboxamide

    		Drug Metabolite Others
    N-Methyl-4-pyridone-3-carboxamide (compound 4PY) is a final product of nicotinamide adenine dinucleotide (NAD) degradation .
    N-Methyl-4-pyridone-3-carboxamide
  • HY-W654288
    NAD+-d4

    β-DPN-d4; β-NAD-d4; β-nicotinamide adenine dinucleotide-d4

    		 Isotope-Labeled Compounds Others
    NAD+-d4 is the deuterium-labeled NAD+ (HY-B0445). NAD+-d4 is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
    NAD+-d4
  • HY-B0445S
    NAD+-13C5 ammonium

    β-DPN-13C5 ammonium; β-NAD-13C5 ammonium; β-nicotinamide adenine dinucleotide-13C5 ammonium

    		 Isotope-Labeled Compounds Metabolic Disease
    NAD+-13C5 (ammonium) is the 13C labled NAD+ (HY-B0445), with an ammonium .
    NAD+-13C5 ammonium
  • HY-P3185
    beta-Galactose dehydrogenase

    		Biochemical Assay Reagents Metabolic Disease
    Beta-galactose dehydrogenase is a selective catalyst for β-galactose. Under pH 8.6 conditions, beta-galactose dehydrogenase catalyzes the oxidation of β-galactose, produced by the hydrolysis of lactose by β-galactosidase, with nicotinamide adenine dinucleotide (NAD) to produce reduced nicotinamide adenine dinucleotide (NADH). Beta-galactose dehydrogenase specifically mediates this oxidation reaction for the quantitative detection of the substrate, used in the analysis of lactose concentration in samples such as breast milk .
    beta-Galactose dehydrogenase
  • HY-131924
    Thionicotinamide adenine dinucleotide

    Thio-NAD

    		 Biochemical Assay Reagents Others
    Thionicotinamide adenine dinucleotide (Thio-NAD) is a thione-modified analog of the coenzyme nicotinamide adenine dinucleotide (NAD +). Thionicotinamide adenine dinucleotide can replace NAD + in enzymatic reactions and shift the absorption peak to 405 nM, enabling sensitive, real-time kinetic detection of enzyme activity, which is particularly suitable for high-sensitivity diagnostic cyclic detection systems .
    Thionicotinamide adenine dinucleotide
  • HY-B0445GL
    NAD+ (GMP Like)

    β-DPN (GMP Like); β-NAD (GMP Like); β-nicotinamide adenine dinucleotide (GMP Like)

    		 Endogenous Metabolite Metabolic Disease
    NAD+ (GMP Like) is NAD+ (HY-B0445) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
    NAD+ (GMP Like)
  • HY-B0445B
    α-NAD

    α-nicotinamide adenine dinucleotide

    		 Mitochondrial Metabolism Endogenous Metabolite Metabolic Disease
    α-NAD (α-Nicotinamide Adenine Dinucleotide) serves as a substrate for reninase, functions as an analog of β-NAD, affects the kinetics of NAD-dependent enzymes, and also plays a critical role as a cofactor in mitochondrial redox reactions .
    α-NAD
  • HY-131485
    3-Acetylpyridine adenine dinucleotide, 90%

    3-APAD, 90%; 3-Acetylpyridine NAD, 90%

    		 Lactate Dehydrogenase Metabolic Disease
    3-Acetylpyridine adenine dinucleotide, 90% is an analog of nicotinamide adenine dinucleotide (NAD). 33-Acetylpyridine adenine dinucleotide, 90% collaboratively inhibits Lactate Dehydrogenase (LDH) with bisulfite .
    3-Acetylpyridine adenine dinucleotide, 90%
  • HY-W250163
    NAD+ lithium
    40+ Cited Publications

    β-DPN lithium; β-NAD lithium; β-nicotinamide adenine dinucleotide lithium

    		 Biochemical Assay Reagents Metabolic Disease
    NAD+ lithium (β-DPN lithium) is a lithium salt of nicotinamide adenine dinucleotide. NAD+ is a coenzyme in the REDOX reaction. NAD+ can directly or indirectly affect several key cellular functions, including metabolic pathways, DNA repair, chromatin remodeling, cell aging, and immune cell function .
    NAD+ lithium
  • HY-137672A
    2',3'-Cyclic NADP disodium

    2',3'-cNADP+; β-nicotinamide adenine dinucleotide-2',3'-cyclic phosphate

    		 Phosphodiesterase (PDE) Calcium Channel Neurological Disease
    2',3'-Cyclic NADP disodium (2',3'-cNADP+; β-Nicotinamide adenine dinucleotide-2',3'-cyclic phosphate) is a substrate for 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), an enzyme abundant in myelin. It has been used in a coupled enzyme assay to quantify CNP activity. 2',3'-Cyclic NADP disodium (5 μM) increases calcium overload-induced calcium release and prevents calcium-induced swelling in rat brain mitochondria.
    2',3'-Cyclic NADP disodium
  • HY-171213
    NB-3

    		Toll-like Receptor (TLR) Neurological Disease
    NB-3 is a nicotinamide adenine dinucleotide (NAD) hydrolase SARM1 inhibitor. NB-3 intercepts NAD hydrolysis and undergoes covalent conjugation with the reaction product adenosine diphosphate ribose (ADPR). The resulting small-molecule ADPR adducts are highly potent and confer compelling neuroprotection in neurological injury .
    NB-3
  • HY-125863C
    Glucose-6-phosphate dehydrogenase, Bacillus sp.

    G6PD, Bacillus sp.

    		 Endogenous Metabolite Others
    Glucose-6-phosphate dehydrogenase, Bacillus sp. catalyzes the conversion of glucose-6-phosphate into 6-phosphogluconolactone, and produces reduced nicotinamide adenine dinucleotide phosphate (NADPH) and ribose-5-phosphate in this process. Glucose-6-phosphate dehydrogenase, Bacillus sp. can be used in research about diabetic complications .
    Glucose-6-phosphate dehydrogenase, Bacillus sp.
  • HY-14374
    GPP78
    1 Publications Verification

    CAY10618

    		 NAMPT Autophagy Inflammation/Immunology Cancer
    GPP78 (CAY10618) is a potent Nampt inhibitor with an IC50 of 3.0 nM for nicotinamide adenine dinucleotide (NAD) depletion. GPP78 is cytotoxic to neuroblastoma cell line SH-SY5Y cells with an IC50 of 3.8 nM by inducing autophagy. GPP78 has anti-cancer and anti-inflammatory effects .
    GPP78
  • HY-E70410
    NAD Synthetase

    NAD+ Synthetase; nicotinamide adenine dinucleotide synthetase

    		 Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    NAD synthetase is responsible for the final step in the synthesis of nicotinamide adenine dinucleotide (NAD). The Km values for NAD, ATP, and ammonia of NAD synthetase from Escherichia coli are 200 μM, 11 μM, and 0.65 μM, respectively, while the Km values for NAD, ATP, and ammonia of NAD synthetase from yeast are 170 μM, 190 μM, and 64 μM, respectively. NAD synthetase can be used for enzymatic assays to determine ATP, ammonia, urea, or creatinine, and is also suitable for enzymatic cycling methods. Additionally, NAD synthetase holds potential for research into metabolic diseases, cancer, aging, and neurodegenerative diseases .
    NAD Synthetase
  • HY-113432S
    Nudifloramide-d3

    		Endogenous Metabolite PARP Metabolic Disease
    Nudifloramide-d3 (2PY-d3) is the deuterium labeled Nudifloramide. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .
    Nudifloramide-d3
  • HY-W250154
    β-Nicotinamide adenine dinucleotide reduced dipotassium

    		Endogenous Metabolite Metabolic Disease
    β-Nicotinamide adenine dinucleotide reduced dipotassium is an orally active reduced coenzyme. β-Nicotinamide adenine dinucleotide reduced dipotassium is a donor of ADP-ribose units in ADP-ribosylaton reactions and a precursor of cyclic ADP-ribose. β-Nicotinamide adenine dinucleotide reduced dipotassium plays a role as a regenerative electron donor in cellular energy metabolism, including glycolysis, β-oxidation and the tricarboxylic acid (TCA) cycle .
    β-Nicotinamide adenine dinucleotide reduced dipotassium
  • HY-151936
    LmNADK1-IN-1

    		Bacterial Infection
    LmNADK1-IN-1 (compound MC1) is an inhibitor of nicotinamide adenine dinucleotide kinases (NADK1) from L. monocytogenes with a Ki value of 54 nM. LmNADK1-IN-1 can be used for the research of bacterial infection . LmNADK1-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    LmNADK1-IN-1
  • HY-B0445AR
    NAD sodium (Standard)

    β-DPN sodium (Standard); β-NAD sodium (Standard); β-nicotinamide adenine dinucleotide sodium (Standard)

    		 Endogenous Metabolite Reference Standards Metabolic Disease
    NAD sodium (Standard) is the analytical standard of NAD sodium. This product is intended for research and analytical applications. NAD (β-Nicotinamide Adenine Dinucleotide) sodium is an analogue of NAD. NAD sodium can be reduced to β-nicotinamide adenine dinucleotide (NADH) during coupling with reactions which oxidize organic substrates. NAD sodium can be converted to β-nicotinamide adenine dinucleotide (NADH) and passes to the inside of mitochondria that indirectly generates ATP .
    NAD sodium (Standard)
  • HY-E70406
    Cholesterol Dehydrogenase, Nocardia sp.

    CHDH-5

    		 Endogenous Metabolite Others
    Cholesterol Dehydrogenase, Nocardia sp. is an enzyme that uses nicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide phosphate (NAD(P)) as its cofactor in oxidizing cholesterol to form cholest-4-en-3-one. This enzyme oxidizes the hydroxyl group at the 3 position of the sterol ring to form a ketone.
    Cholesterol Dehydrogenase, Nocardia sp.
  • HY-P2940
    NADase

    		NAMPT Inflammation/Immunology
    NADase is an ectoenzyme/membrane-bound enzyme targeting nicotinamide adenine dinucleotide (NAD +). NADase regulates intracellular NAD + homeostasis by hydrolyzing NAD + into nicotinamide mononucleotide (NMN) and ADP-ribose. NADase is promising for research of autoimmune diseases (e.g., systemic sclerosis, systemic lupus erythematosus) and aging-related disorders .
    NADase
  • HY-113432R
    Nudifloramide (Standard)

    2PY (Standard)

    		 Reference Standards Endogenous Metabolite PARP Metabolic Disease
    Nudifloramide (Standard) is the analytical standard of Nudifloramide. This product is intended for research and analytical applications. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .
    Nudifloramide (Standard)
  • HY-131485A
    3-Acetylpyridine adenine dinucleotide, 95%

    3-APAD, 95%; 3-Acetylpyridine NAD, 95%

    		 Lactate Dehydrogenase Metabolic Disease
    3-Acetylpyridine adenine dinucleotide, 95% (3-APAD, 95%)is an analog of nicotinamide adenine dinucleotide (NAD). 33-Acetylpyridine adenine dinucleotide, 95% collaboratively inhibits Lactate Dehydrogenase (LDH) with bisulfite .
    3-Acetylpyridine adenine dinucleotide, 95%
  • HY-134280
    8-Br-NHD+

    nicotinamide 8-Br-hypoxanthine dinucleotide

    		 Drug Derivative Others
    8-Br-NHD+ (Nicotinamide 8-Br-hypoxanthine dinucleotide) is a derivative of NAD+ (nicotinamide adenine dinucleotide) that acts as a potential substrate, competitive inhibitor or modulator of enzymes that interact with β-NAD+. 8-Br-NHD+ can be used to synthesize a cyclic ADP nucleotide (cADPR) analog .
    8-Br-NHD+
  • HY-177842
    Liposomal NAD+

    		Liposome Metabolic Disease
    Liposomal NAD+ is a specialized delivery system that encapsulates NAD+ within tiny liposomes. These liposomes act as protective shells, enhancing the absorption and bioavailability of NAD+. NAD+ (β-Nicotinamide adenine dinucleotide), also known as Coenzym
    Liposomal NAD+
  • HY-172919
    PDEδ/NAMPT IN-1

    		Phosphodiesterase (PDE) NAMPT Apoptosis Cancer
    PDEδ/NAMPT IN-1 (Compound 17d) is a dual inhibitor targeting phosphodiesterase 6 (PDE6) (KD=0.410 nM) and nicotinamide phosphoribosyl transferase (NAMPT) (IC50=2.21 nM). PDEδ/NAMPT IN-1 blocks KRAS-related signal transduction and interferes with the synthesis of nicotinamide adenine dinucleotide (NAD +), inducing apoptosis in KRAS mutant pancreatic cancer cells. PDEδ/NAMPT IN-1 is promising for research of KRAS mutant pancreatic cancer .
    PDEδ/NAMPT IN-1
  • HY-156424
    NOX2-IN-1

    		NADPH Oxidase Inflammation/Immunology
    NOX2-IN-1 (compound 10) is an inhibitor of nicotinamide adenine dinucleotide phosphate oxidase isoform 2 (NOX2). NOX2-IN-1 targets the p47phox p22phox protein protein interaction with favorable binding affinities and cellular activities .
    NOX2-IN-1
  • HY-134355
    ADPRP

    		PARP Others
    ADPRP is an intranuclear enzyme whose main activity is to use NAD+ (nicotinamide adenine dinucleotide) as a substrate to add ADP-ribose units to chromatin-bound proteins, including the ADPRP enzyme itself. This process, called poly(ADP-ribosylation), is a post-translational modification that regulates the interaction between DNA and nuclear proteins .
    ADPRP
  • HY-186105
    P7C3-S243

    		NAMPT Neurological Disease
    P7C3-S243 is a brain-penetrant P7C3 class of neuroprotective agent. P7C3-S243 augments synthesis of nicotinamide adenine dinucleotide through activation of the metabolic enzyme nicotinamide phosphoribosyltransferase. P7C3-S243 shows potent neuroprotective efficacy in parkinson’s disease mice models. P7C3-S243 can be used for the research of parkinson’s disease .
    P7C3-S243
  • HY-171416
    LCD36

    		Drug Derivative Others
    LCD36, a derivative of nicotinamide adenine dinucleotide (NAD), can be used for synthesis of PARP-1 tracers for positron emission tomography (PET) imaging of the enzyme activity of PARP-1 .
    LCD36
  • HY-134392A
    6-Alkyne-NAD+ sodium

    		Nucleoside Antimetabolite/Analog Others
    6-Alkyne-NAD+ sodium is a nicotinamide adenine dinucleotide (NAD) analogue. 6-Alkyne-NAD+ sodium can be used as a fluorescent probe coupled with fluorescent labels for marking ADP-ribose polymerase substrate proteins .
    6-Alkyne-NAD+ sodium
  • HY-125863D
    Glucose-6-phosphate dehydrogenase, Torula yeast

    		Endogenous Metabolite Metabolic Disease
    Glucose-6-phosphate dehydrogenase, Torula yeast (EC 1.1.1.49), is a cytoplasmic enzyme located in the pentose phosphate pathway, a metabolic pathway that provides reducing energy to cells (e.g., erythrocytes) by maintaining the level of the coenzyme nicotinamide adenine dinucleotide phosphate (NADPH).
    Glucose-6-phosphate dehydrogenase, Torula yeast
  • HY-E71039
    Chemically modified Glucose-6-phosphate Dehydrogenase, Leuconostoc mesenteroides

    		Biochemical Assay Reagents Others
    Chemically modified Glucose-6-phosphate Dehydrogenase, Leuconostoc mesenteroides is a cytosolic enzyme. Chemically modified Glucose-6-phosphate Dehydrogenase, Leuconostoc mesenteroides is in the pentose phosphate pathway, a metabolic pathway that supplies reducing energy to cells (such as erythrocytes) by maintaining the level of the co-enzyme nicotinamide adenine dinucleotide phosphate (NADPH) .
    Chemically modified Glucose-6-phosphate Dehydrogenase, Leuconostoc mesenteroides
  • HY-113432S2
    Nudifloramide-13C,d3

    2PY-13C,d3

    		 Isotope-Labeled Compounds Endogenous Metabolite PARP Metabolic Disease
    Nudifloramide- 13C,d3 (2PY- 13C,d3) is the 13C- and deuterium labeled Nudifloramide (HY-113432). Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .
    Nudifloramide-13C,d3
  • HY-182025
    NAD+ potentiator-1

    		Endogenous Metabolite Neurological Disease
    NAD+ potentiator-1 (Compound R-4b) is a NAD potentiator. NAD+ potentiator-1 increases NAD levels in primary cortical neurons. NAD+ potentiator-1 is used for the research of neurodegenerative diseases .
    NAD+ potentiator-1
  • HY-181542
    SG-55

    		Aldose Reductase Cancer
    SG-55 is a selective, noncompetitive and orally active AKR1C3 inhibitor with an IC50 of 5 nM and a Ki of 10 nM. SG-55 shows >2000-fold selectivity for AKR1C3 over AKR1C1, AKR1C2, and AKR1C4 (> 10 μM). SG-55 increases the ratio of reduced/oxidized nicotinamide adenine dinucleotide phosphate (NADPH/NADP +), decreases the ratio of reduced/oxidized glutathione (GSH/GSSG), and induces DNA double-strand breaks. SG-55 can overcome Osimertinib (HY-15772) resistance mediated by EGFR C797S triple mutation in non-small cell lung cancer (NSCLC) .
    SG-55

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: